Bloomberg reported that Pfizer and its partner Medivation may release

findings from a Phase III study investigating Dimebon (dimebolin) in patients

with Alzheimer’s disease in the first week of March, according to Bengt

Winblad of the Karolinska Institute who is leading European trials of the drug.

The companies are hoping that results of the 525-patient trial mirror those of an earlier study, which showed

that patients with Alzheimer’s disease who received Dimebon had an improvement in their symptoms

compared to those who received placebo. However, Briggs Morrison, senior vice president of Pfizer’s

primary-care development group and Medivation CEO David Hung said that the data from the trial will be released by July.

Samuel Gandy of the Mount Sinai School of Medicine noted that the earlier study, published in The Lancet in

2008, “showed the most effective and sustained benefit that we’ve ever seen in Alzheimer’s. There is nothing that’s currently approved that compares to it and nothing else really in the pipeline that compares to it.”

Analysts expect the companies to file for approval of the drug in 2011, although the companies noted that

data from the CONNECTION study could bring that date forward. Cowen & Co. analyst Ian Sanderson said that if the results are confirmed, the drug, which Pfizer licensed from Medivation in September 2008, could

generate annual revenue of $1.6 billion by 2015.

المفضلة

إرسال إلى صديق

التعليقات (0)

أضف تعليق

الإسم

البريد الإلكتروني

العنوان

التعليق

تصغير | تكبير

أضف تعليق